> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eli Lilly Stock Surges 7%, Adding $77 Billion, As Mounjaro Sales Jump 65% And Revenue Outlook Rises
- URL: https://www.bullished.co/eli-lilly-stock-surges-7-adding-77-billion-as-mounjaro-sales-jump-65-and-revenue-outlook-44126996/
- Published: 2026-10-29T14:50:39.000Z
- Updated: 2026-10-29T14:50:39.000Z
- Description: Shares hit a 52-week high after Lilly raised its 2026 sales forecast, though deal charges trimmed its adjusted profit outlook.
- Author: Matteo Parrino
- Tags: Markets, LLY, Industry: Healthcare

[Eli Lilly](https://www.bullished.co/tag/lly/), the drugmaker behind the diabetes and obesity treatments Mounjaro and Zepbound, saw its shares climb 6.67% to $1374.29 in Thursday trading as of 10:49 a.m. ET, adding $77 billion in market value, after it reported third-quarter revenue of [$24.4 billion](https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html?ref=bullished.co) and raised its full-year sales forecast for the third time this year.

## A $5.5 billion bump to the forecast

Lilly [raised its 2026 revenue forecast](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full?ref=bullished.co) to $91 billion to $92 billion, from $85 billion to $87 billion. That is $5.5 billion higher at the midpoint.

Mounjaro sales jumped 65% to $10.72 billion in the third quarter. Zepbound sales reached $5.35 billion, up 49% from a year earlier, [CNBC reported](https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html?ref=bullished.co).

Foundayo, Lilly's weight-loss pill, [generated $184 million](https://seekingalpha.com/news/4660034-eli-lilly-lifts-sales-outlook-as-blockbuster-weight-loss-drugs-fuel-growth?ref=bullished.co) in third-quarter sales, short of the roughly [$229 million analysts expected](https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html?ref=bullished.co), according to CNBC.

## Deal charges trim the profit outlook

Lilly now projects [2026 adjusted earnings](https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html?ref=bullished.co) of $35 to $36 a share, below the prior $35.50 to $36.50\. The company said $4.57 a share in deal-related research charges offset a $4.07 underlying increase.

## A record run for the stock

The shares touched a new 52-week high of $1374.29 on Thursday and were on pace for their biggest one-day gain since June 26, when they rose 7.1%.

They were already up about 20% year to date at Wednesday's close, against about 13% for the S&P 500\. They had been within 2% of their highest close of the past year, set October 22, and were heading for a fourth straight daily gain.

Lilly develops, manufactures and markets human pharmaceuticals as a single business. Its lineup spans diabetes and obesity, cancer, immune and neurological conditions. In the prior reported quarter, it posted [revenue of $23 billion](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm?ref=bullished.co), up 47.7% from a year earlier, with net income of $7.1 billion.

Thursday's quarter put Lilly's full-year revenue guidance at $91 billion to $92 billion, with Mounjaro and Zepbound together bringing in more than $16 billion in the third quarter alone.

### Sources

- [Eli Lilly (LLY) earnings Q3 2026](https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html?ref=bullished.co) — CNBC
- [Eli Lilly stock jumps as drugmaker raises outlook on booming sales of diabetes and obesity treatments](https://finance.yahoo.com/markets/stocks/article/eli-lilly-stock-jumps-as-company-raises-revenue-guidance-135516565.html?ref=bullished.co) — Yahoo Finance
- [Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance | Investor's Business Daily](https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q3-2026/?ref=bullished.co) — investors.com
- [Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.](https://www.marketwatch.com/story/lilly-raises-outlook-for-third-time-this-year-as-zepbound-sales-soar-6d987407?mod=markets&ref=bullished.co) — MarketWatch
- [Eli Lilly lifts sales outlook as blockbuster weight-loss drugs fuel growth (LLY:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4660034-eli-lilly-lifts-sales-outlook-as-blockbuster-weight-loss-drugs-fuel-growth?ref=bullished.co) — seekingalpha.com
- [The company's filing (Eli Lilly and Co.)](https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000104/lly-20261029.htm?ref=bullished.co) — SEC filing
- [The company's announcement (Eli Lilly and Co.)](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full?ref=bullished.co) — the company
- [Eli Lilly and Co. — Form 10-Q for the quarter ended 2026-06-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm?ref=bullished.co) — SEC EDGAR

### More on Eli Lilly and

- [Lilly Lifts 2026 Revenue Outlook To $91 Billion-$92 Billion, But $4.57 A Share In Deal Charges Cuts Profit Forecast](https://www.bullished.co/lilly-lifts-2026-revenue-outlook-to-91-billion-92-billion-but-4-57-a-share-in-deal-charges-2cdfbec8/)

[All Eli Lilly and (LLY) coverage →](https://www.bullished.co/tag/lly/)